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Abstracts / Biol Blood Marrow Transplant 20 (2014) S104eS127S106Myeloma subtype, ISS, post-ASCT response and PET activity
were signiﬁcantly associated with PFS. Post-ASCT PET(-) CR
had signiﬁcantly longer PFS than patients with PET(+) CR
(31.4  9.9 vs 18.4  3.5 months; p¼.029). In conclusion,
having an ISS-3 stage myeloma, pre and post-ASCT response
<VGPR had negative impact on PFS. Contamination of PBSC
harvests with APC was associated with shorter PFS. Our re-
sults also demonstrate the importance of achieving PET
negativity after transplantation. Thus, not only an immuno-
logical CR but also PET(-) CR should be achieved for long
term PFS.128
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Introduction: High-dose therapy with AutoHCT is a stan-
dard component of therapy for many patients with Hodgkin
(HL) and non-Hodgkin lymphoma (NHL). IPS is a known
toxicity of AutoHCT which can cause signiﬁcant morbidity
and mortality. The most common agent associated with IPS
has traditionally been high-dose BCNU (carmustine). Data on
incidence of IPS in recent era and its relation with condi-
tioning regimens are scarce.
Methods and Patients: Using the Center for International
Bone Marrow Transplant Registry (CIBMTR), we studied
4,573 patients with lymphoma who underwent AutoHCT
from 1995-2008 using the following conditioning regimens:
BEAM (n¼1730), CBVlow (n¼1249), CBVhigh (n¼604), BuCy
(n¼789), and CyTBI (n¼545). We investigated the reported
incidence of and explored clinical risk factors for its devel-
opment, including the dose of BCNU and its impact on
outcome (above vs. below 375 mg/m2 in CBV regimens). We
then analyzed the impact of IPS on outcomes including
transplant-related mortality (TRM), progression-free sur-
vival (PFS), and overall survival (OS). Use of different regi-
mens was as follows:
Results: The incidence of IPS by 1 year after AutoHCT was:
BEAM (3%), CBVlow (3%, HR 1.07 [0.72,1.60], p¼0.742), CBVhigh
(6%, HR 1.88 [1.24, 2.83], p¼0.003), BuCy (4%, HR 1.25 [0.82,1.92], p¼.30), and CyTBI (5%, HR 2.03 [1.30, 3.19], p¼.002).
Multivariate analysis showed the following risk factors for
developing IPS: 1) HL (HR 2.33, [1.68, 3.24], p < .001), 2)
female gender (HR 1.39 [1.05, 1.82], p¼.019), 3) chemo-
therapy-resistant disease at time of AutoHCT (HR 1.9 [1.29,
2.79], p¼.001), and age 55 (HR 1.54, [1.13, 2.09], p¼.006). In
the entire cohort, patients who developed IPS had a signiﬁ-
cantly higher rate of TRM (HR 4.02, [3.09, 5.24], p < .001),
shorter PFS (HR 1.82, [1.51, 2.20], p < .001), and shorter OS
(HR 2.46, [2.06, 2.94], p < .001).
Conclusion: IPS remains an important toxicity after AutoHCT
for patients with lymphoma and adversely effects overall
outcomes. Risk factors include higher doses of BCNU, TBI,
female gender, older age, chemotherapy resistant disease
and a diagnosis of HL. Investigation into strategies for the
prevention of IPS after ASCT is warranted.129
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The importance of optimal long term engraftment after
autologous stem cell transplantation is uncertain. We con-
ducted a retrospective analysis of long term engraftment in
patients who underwent autologous peripheral blood stem
cell transplant for non-Hodgkin lymphoma, Hodgkin lym-
phoma or multiple myeloma. Patients who relapsed or died
prior to assessment of long term engraftment at 1 year were
excluded. Optimal engraftment was deﬁned by NCI CTCAE
grade 1 criteria for cytopenias (ANC  1500/ml, platelets 
75000/ml, hemoglobin  10g/dL). 225 patients were iden-
tiﬁed with engraftment data at 1 year (92 NHL, 62 HL, 71
MM). Themedian follow-upwas 5.0 years for all patients (5.5
for living patients).
88% of patients achieved optimal engraftment at 1 year. The
median cell dose was 4.7 x10
ˇ
6 CD34+ cells/kg, and our
institutional minimum cell dose is 2 x10
ˇ
6 CD34+ cells/ kg.
CD34 cell dose  3 x10 ˇ6 CD34+ cells/kg and age < 60 were
predictive for optimal long term engraftment. Disease type,
gender, number of prior therapies and prior radiation ther-
apy were not predictive of achieving long term engraftment.
By landmark analysis at 1 year, optimal engraftment was not
predictive for progression free survival or overall survival in
all patients, although there was a trend for worse outcome
with poor engraftment in HL and NHL.
Incomplete long term engraftment after autologous trans-
plant is relatively rare with the most important predictors
identiﬁed as CD34 cell dose and age. For those patients who
survive one year, PFS and OS are not diminished afterward.130
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